Japan RNA Bioventure Ribomic Set To Float
This article was originally published in PharmAsia News
Executive Summary
Ribomic, a biopharmaceutical startup in Japan, is about to go public on the Mothers market of the Tokyo Stock Exchange, betting on its ability to manipulate RNA to develop novel drugs.